Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Combined With HAIC-FOLFOX for Advanced HCC
NCT02981498Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2015
- Primary completion
- Apr 2017
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-free survival rate at 3 months. Started Jun 2015; status: completed.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02981498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981498.